Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury
Status:
Enrolling by invitation
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Randomized, placebo controlled study to determine if nebulized heparin may reduce the
severity of lung injury caused by the novel coronavirus, also known as COVID-19